Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
Top Cited Papers
- 21 March 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 379 (9826), 1602-1612
- https://doi.org/10.1016/s0140-6736(11)61720-0
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trialsThe Lancet, 2012
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2011
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2010
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Aspirin, salicylates, and cancerThe Lancet, 2009
- Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: An example from the Mayo Lung ProjectLung Cancer, 2008
- Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet, 2007
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005